Walder Wyss Ltd.
Primarily based in Zurich, Walder Wyss Ltd. is noted for assisting healthcare and life sciences associations, healthcare insurance companies, and large hospitals. Practice co-head Michael Isler handles a broad range of technology related issues, including outsourcing, platform, and transfer projects. Working from both the Zurich and Bern offices, co-head Andreas Wildi primarily assists clients with domestic and international reimbursement and pricing mandates. Martin Zobl has deep expertise in public procurement matters, having handled a range of disputes before administrative bodies.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘Excellent team, superb dedication to projects, very fast response time, great friendliness, they bring valuable input and ideas, very open for feedback, easy going, worked on a number of contracts with them and they really understand the business’
‘Deep insights in the system. Agile adaption to new situations. Very quick reaction times.’
‘Walder Swiss has a deep knowledge of reimbursement in the Swiss health care system. This was very useful for us.’
‘High level of engagement, high level of expertise, structured approach to problem solving. ’
‘Employees have a very in-depth and outstanding technical expertise. Due to the size of the team, the most diverse needs can be delivered with the best quality.’
‘Very well coordinated team, which solves tasks together according to the needs and requests of clients. A wide variety of technical specialists are available.’
‘Andreas Wildi has a huge experience knows the hurdles of the Swiss healthcare market, extremely good, quick response time, very competent.’
Key clients
- Pfizer AG
- Sanofi-Aventis (Schweiz) AG
- Recordati AG
- Swiss Medical Association
- Hirslanden AG
- ExcellGene SA
- Neuraxpharm Switzerland AG
- MediService AG
- Vereinigung Pharmafirmen in der Schweiz
- OrPha Swiss GmbH
- Merz Pharma (Schweiz) AG
- BeiGene Switzerland GmbH
- Verein Berufliche Grundbildung Augenoptik
- OPTIKSCHWEIZ
- Institute of Molecular and Clinical Ophthalmology Basel (IOB)
- Exact Sciences International GmbH
- Daiichi Sankyo (Schweiz) AG
- Johner Institut Schweiz GmbH
- Biogen Switzerland AG
- Ufenau Capital Partners AG
- Emeda AG
- Lundbeck GmbH
- KKS Ultraschall AG
Work highlights
- Advised and represented Pfizer in various price reduction and access to confidential pricing models proceedings before the Federal Administrative Court and advised Sanofi-Aventis (Schweiz) AG on various market access (pricing & reimbursement) inquiries.
- Advising and representing various privately held hospitals of the Hirslanden Group in hospital planning proceedings in numerous Swiss Cantons (regular hospital planning being a cantonal matter, aiming at awarding public performance mandates for certain medical disciplines of public interest), and in 13 inter-cantonal planning proceedings in the field of highly specialized medical services before the inter-cantonal planning body in charge and the Federal Administrative Court.
- Represented Neuraxpharm Switzerland AG before Swissmedic resulting in a change of practice on the part of Swissmedic, advised OptikSchweiz to initiate and successfully realize a change in the implementation provisions of the law, advised the leading pharma association VIPS in the preparation of statements towards the Swiss Government and provided a legal opinion to Swiss Medical Association (FMH) on the impact of the new medical device regulation for healthcare providers using medical device software.
Practice head
The lawyer(s) leading their teams.
Michael Isler, Andreas Wildi